In addition, EPHA2-FC soluble receptors were shown to significantly reduce tumor volume and overall metastatic burden in pre-clinical models of breast [52] and pancreatic tumors [53], but have not been evaluated in colorectal cancer models. The gene discussed is EPHA2; the disease is colorectal cancer.